Raymond H Kim
Overview
Explore the profile of Raymond H Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
2775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanabria-Salas M, Anggala N, Gillies B, Farncombe K, Hofstedter R, Peck L, et al.
BMC Cancer
. 2025 Jan;
25(1):176.
PMID: 39885482
Background: Integrating germline genetic testing (GGT) recommendations from tumor testing into hereditary cancer clinics and precision oncology trials presents challenges that require multidisciplinary expertise and infrastructure. While there have been...
2.
Clausen M, Krishnapillai S, Hirjikaka D, Kodida R, Shickh S, Reble E, et al.
Genet Med Open
. 2024 Dec;
2:101814.
PMID: 39669596
Purpose: Increasing demand for genomic testing coupled with genetics workforce shortages has placed unsustainable pressure on standard models of care. Digital tools can offer improved access, efficiency, and cost savings....
3.
Shickh S, Mighton C, Clausen M, Sam J, Hirjikaka D, Reble E, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400407.
PMID: 39666930
Purpose: Genomic sequencing (GS) is increasingly used to improve diagnoses and inform targeted therapies. GS can also be used to identify the 10% of cancer patients with an underlying hereditary...
4.
Farncombe K, Hughes L, Tuzlali E, Akbari M, Andrulis I, Aronson M, et al.
BMJ Open
. 2024 Nov;
14(11):e087023.
PMID: 39581712
Introduction: In Canada, care for individuals with hereditary cancer is fragmented across the provinces and territories, with carriers of pathogenic variants in cancer-susceptibility genes seeing multiple doctors and often advocating...
5.
Haq S, Downs G, Zhan L, Schmid S, Patel D, Sacdalan D, et al.
JTO Clin Res Rep
. 2024 Nov;
5(12):100702.
PMID: 39564094
Introduction: SCLC has traditionally been considered to arise from toxic exposure factors, such as smoking. Recent evidence has revealed that germline mutations may also affect the development of SCLC; however,...
6.
Mighton C, Kodida R, Shickh S, Clausen M, Reble E, Sam J, et al.
Genet Med
. 2024 Nov;
27(2):101323.
PMID: 39530317
Purpose: Practice is shifting toward genome-first approaches, such as opportunistic screening for secondary findings (SFs). Analysis of SFs could be extended beyond medically actionable results to include non-medically actionable monogenic...
7.
Kim S, Oldfield L, Kim R, Espin-Garcia O, Han K, Vicus D, et al.
J Surg Oncol
. 2024 Nov;
PMID: 39501493
Background And Objectives: Adoption of molecular classification in endometrial cancer (EC) into clinical practice remains challenging due to complexity in coordination of multiple assays. We aimed to develop a simple...
8.
Phillips K, Kotsopoulos J, Domchek S, Terry M, Chamberlain J, Bassett J, et al.
J Clin Oncol
. 2024 Oct;
43(4):422-431.
PMID: 39356978
Purpose: It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline or mutation carriers. Methods: Using pooled observational data from four prospective cohort...
9.
Wong D, Tageldein M, Luo P, Ensminger E, Bruce J, Oldfield L, et al.
Nat Commun
. 2024 Aug;
15(1):7386.
PMID: 39191772
Germline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that...
10.
Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky B, Moller P, Kim R, et al.
Gynecol Oncol
. 2024 Aug;
189:148-155.
PMID: 39173195
Objective: Whether or not women who harbor a germline pathogenic variant ('mutation') in the BRCA1 or BRCA2 genes are at elevated risk of developing endometrial cancer is yet to be...